A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).

Trial Profile

A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Darapladib (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms SOLID-TIMI52
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 Nov 2016 Results assessing the risk of adverse limb events in patients with peripheral artery disease post-acute coronary syndrome (n=13009), presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 13 May 2014 Top-line results reported in a GlaxoSmithKline media release.
    • 13 May 2014 Primary endpoint 'Superiority of darapladib vs placebo in reduction in major-adverse-cardiac-event-rate' has not been met, according to a GlaxoSmithKline media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top